Susquehanna International Group’s Novavax NVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.8M Buy
834,842
+403,223
+93% +$3.66M ﹤0.01% 3719
2025
Q4
$2.9M Sell
431,619
-298,337
-41% -$2.25M ﹤0.01% 4924
2025
Q3
$6.33M Sell
729,956
-201,770
-22% -$1.57M ﹤0.01% 3724
2025
Q2
$5.87M Buy
931,726
+457,417
+96% +$3.03M ﹤0.01% 3677
2025
Q1
$3.04M Buy
474,309
+363,153
+327% +$3M ﹤0.01% 4623
2024
Q4
$894K Buy
111,156
+44,614
+67% +$430K ﹤0.01% 7248
2024
Q3
$840K Sell
66,542
-78,398
-54% -$1.01M ﹤0.01% 7212
2024
Q2
$1.83M Sell
144,940
-106,011
-42% -$1.07M ﹤0.01% 5259
2024
Q1
$1.2M Buy
250,951
+213,412
+569% +$990K ﹤0.01% 6454
2023
Q4
$180K Sell
37,539
-162,272
-81% -$993K ﹤0.01% 10790
2023
Q3
$1.45M Sell
199,811
-130,190
-39% -$1.04M ﹤0.01% 5811
2023
Q2
$2.45M Sell
330,001
-228,281
-41% -$1.8M ﹤0.01% 4728
2023
Q1
$3.87M Buy
558,282
+382,348
+217% +$3.52M ﹤0.01% 3848
2022
Q4
$1.81M Buy
175,934
+115,358
+190% +$2.04M ﹤0.01% 4902
2022
Q3
$1.1M Sell
60,576
-242,224
-80% -$10.5M ﹤0.01% 6389
2022
Q2
$15.6M Sell
302,800
-1,028,318
-77% -$53.3M ﹤0.01% 1684
2022
Q1
$98M Buy
1,331,118
+66,946
+5% +$5.97M 0.02% 664
2021
Q4
$181M Sell
1,264,172
-106,982
-8% -$18.4M 0.03% 498
2021
Q3
$284M Buy
1,371,154
+700,509
+104% +$154M 0.04% 393
2021
Q2
$142M Buy
670,645
+175,040
+35% +$32.1M 0.02% 646
2021
Q1
$89.9M Sell
495,605
-744,342
-60% -$148M 0.01% 784
2020
Q4
$138M Buy
1,239,947
+715,863
+137% +$76.1M 0.02% 541
2020
Q3
$56.8M Buy
524,084
+387,417
+283% +$47.2M 0.01% 810
2020
Q2
$11.4M Sell
136,667
-116,549
-46% -$4.46M ﹤0.01% 1995
2020
Q1
$3.44M Buy
+253,216
New +$2.14M ﹤0.01% 3086
2019
Q4
Sell
-12,838
Closed -$55.7K 10341
2019
Q3
$64K Buy
+12,838
New +$70.3K ﹤0.01% 9711
2019
Q1
Sell
-59,842
Closed -$1.89M 9520
2018
Q4
$2.2M Buy
59,842
+39,216
+190% +$1.52M ﹤0.01% 3386
2018
Q3
$776K Sell
20,626
-21,460
-51% -$604K ﹤0.01% 5735
2018
Q2
$1.13M Buy
42,086
+32,064
+320% +$1.08M ﹤0.01% 5082
2018
Q1
$421K Sell
10,022
-58,304
-85% -$2.34M ﹤0.01% 6979
2017
Q4
$1.69M Buy
68,326
+937
+1% +$22.9K ﹤0.01% 4212
2017
Q3
$1.54M Buy
67,389
+25,491
+61% +$571K ﹤0.01% 4411
2017
Q2
$964K Buy
41,898
+15,328
+58% +$301K ﹤0.01% 5341
2017
Q1
$680K Buy
26,570
+19,589
+281% +$539K ﹤0.01% 5931
2016
Q4
$176K Sell
6,981
-44,428
-86% -$1.3M ﹤0.01% 8748
2016
Q3
$2.14M Buy
51,409
+45,651
+793% +$5.89M ﹤0.01% 3460
2016
Q2
$837K Sell
5,758
-27,323
-83% -$3.13M ﹤0.01% 5212
2016
Q1
$3.41M Buy
33,081
+3,525
+12% +$378K ﹤0.01% 2857
2015
Q4
$4.96M Buy
29,556
+10,992
+59% +$1.69M ﹤0.01% 2553
2015
Q3
$2.63M Buy
18,564
+13,844
+293% +$3.1M ﹤0.01% 3755
2015
Q2
$1.05M Sell
4,720
-116,228
-96% -$20.4M ﹤0.01% 6120
2015
Q1
$20M Buy
120,948
+98,111
+430% +$15.9M 0.01% 1237
2014
Q4
$2.71M Buy
22,837
+5,700
+33% +$596K ﹤0.01% 3910
2014
Q3
$1.43M Sell
17,137
-70,155
-80% -$6.34M ﹤0.01% 5231
2014
Q2
$8.07M Buy
87,292
+69,983
+404% +$6.15M ﹤0.01% 2383
2014
Q1
$1.57M Sell
17,309
-1,985
-10% -$222K ﹤0.01% 4731
2013
Q4
$1.98M Buy
19,294
+524
+3% +$37K ﹤0.01% 4289
2013
Q3
$1.18M Buy
+18,770
New +$1.06M ﹤0.01% 4992

Other funds holding NVAX

Susquehanna International Group's NVAX Position: Q1 2026 in Review

Susquehanna International Group increased its Novavax (NVAX) stake by 93% in Q1 2026, buying an estimated $3.66M and bringing the position to 834,842 shares worth $6.8M. The position accounts for ﹤0.01% of the portfolio, ranked #3719.

Susquehanna International Group first reported a position in NVAX in Q3 2013 and has held it in 48 quarters since. The position peaked at $284M in Q3 2021. 258 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.

  • Susquehanna International Group held 834,842 shares of Novavax worth $6.8M as of Q1 2026.
  • Susquehanna International Group bought 403,223 Novavax shares in Q1 2026, an estimated $3.66M.
  • Novavax made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #3719 holding.
  • Susquehanna International Group first reported a position in Novavax in Q3 2013 and has held it in 48 quarters since.
  • Susquehanna International Group's Novavax position peaked at $284M in Q3 2021.
  • 258 funds tracked by Wall St. Rank held Novavax as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.